New pill shows promise for rare tumor in japanese patients

NCT ID NCT07170644

Ongoing Disease control Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This phase 2 study tests the drug nirogacestat in 20 Japanese adults with desmoid tumors that are growing. The goal is to see if the drug can shrink tumors or stop them from getting worse. Participants take nirogacestat as an oral tablet, and researchers will monitor tumor response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nirogacestat (oral tablet)
What this could lead to: If successful, nirogacestat could offer a new treatment option for Japanese patients with desmoid tumors, potentially shrinking tumors and delaying progression without surgery.
What could go wrong: This is a small, early-phase study with only 20 participants, so results may not apply to all patients. The drug may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE FIBROMATOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

desmoid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGGRESSIVE FIBROMATOSIS DESMOID TUMOR

Contacts and locations

Locations

Nagoya University Hospital

Nagoya, Aichi-ken, 466-8560, Japan
National Cancer Center Hospital

Chuo Ku, Tokyo, 104-0045, Japan
Osaka International Cancer Institute

Osaka, 541-8567, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.